Burning Rock Biotech Limited (BNR) reports developments in next-generation sequencing technology for precision oncology. Its news commonly covers financial results, Form 20-F annual reporting, annual general meeting actions, ADS-related ownership announcements, and clinical or regulatory updates for NGS assays used in therapy selection, MRD assessment, companion diagnostics and cancer early detection.
Company updates reference products and technologies such as OncoScreen, CanCatch and ELSA-seq, including study publications, patent grants and companion-diagnostic approvals connected to precision oncology testing.
On June 29, 2020, Burning Rock Biotech (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals to co-develop companion diagnostics for pralsetinib, aimed at detecting RET alterations in cancer patients in China. Pralsetinib, an investigational therapy by Blueprint Medicines, has shown promising clinical results, particularly in RET fusion-positive non-small cell lung cancer. Burning Rock is committed to advancing precision diagnostics leveraging next-generation sequencing technology, enhancing patient targeting for therapies.
Burning Rock Biotech Limited (NASDAQ: BNR) announced the full exercise of an over-allotment option in its IPO, allowing for the sale of an additional 2,025,000 American Depositary Shares (ADSs) at US$16.50 each. The total offering size now stands at approximately US$281.2 million. The company has a total of 103,804,534 ordinary shares post-offering, including 86,479,686 Class A shares. The IPO is facilitated by underwriters Morgan Stanley, BofA Securities, and Cowen.